摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol;hydron;chloride

中文名称
——
中文别名
——
英文名称
(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol;hydron;chloride
英文别名
——
(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol;hydron;chloride化学式
CAS
——
化学式
C19H28ClNO
mdl
——
分子量
321.9
InChiKey
OQGYMIIFOSJQSF-DTOXXUQYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    23.5
  • 氢给体数:
    2
  • 氢受体数:
    2

文献信息

  • [EN] PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE<br/>[FR] VÉHICULE D'ADMINISTRATION DE MÉDICAMENTS MULTIPLES À BASE DE PEPTIDES
    申请人:ARIEL-UNIVERSITY RES AND DEV COMPANY LTD
    公开号:WO2017068577A1
    公开(公告)日:2017-04-27
    A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.
    本文提供了一种包括靶向基团、多功能肽平台和附着在其上的多种可控释放的生物活性剂的分子结构。
  • [EN] THERANOSTIC CONJUGATES<br/>[FR] CONJUGUÉS THÉRANOSTIQUES
    申请人:ARIEL SCIENT INNOVATIONS LTD
    公开号:WO2021009759A1
    公开(公告)日:2021-01-21
    Provided herein is a drug delivery (DD) system for ratiometric luminescence determination of drug release degree in drug delivery monitoring, which includes a drug, a switchable reporter and non-switchable reporter providing two distinguishable signals for detection; or a single switchable reporter providing two distinguishable signals for detection, and a cleavable linker connecting a drug to a switchable reporter, as well as a method for ratiometric luminescence determination of drug release in a target in vivo or in vitro), which is effected by administering the DD system provided herein that is capable of releasing a drug from the DD system, measuring two luminescent signals provided by the switchable reporter and the non-switchable reporter, or the single switchable reporter, determining the ratio between these two luminescence signals, and determining the drug release degree through the ratio between the two luminescence signals.
    本文提供了一种药物递送(DD)系统,用于药物递送监测中药物释放程度的比例荧光测定,该系统包括一种药物、一种可切换的报告物和一种不可切换的报告物,用于提供两种可区分的信号以进行检测;或者一种单一可切换的报告物,用于提供两种可区分的信号以进行检测,以及一种可切割的连接剂,连接药物和可切换的报告物,以及一种比例荧光测定方法,用于在目标(体内或体外)中测定药物释放,通过给予本文提供的能够从DD系统中释放药物的DD系统,测量可切换的报告物和不可切换的报告物提供的两个发光信号,或者单一可切换的报告物,确定这两个发光信号之间的比例,并通过这两个发光信号之间的比例确定药物释放程度。
  • Benzoamide piperidine containing compounds and related compounds
    申请人:——
    公开号:US20030087925A1
    公开(公告)日:2003-05-08
    The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by helicobacter pylori, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.
    本发明涉及某些含有苯甲酰胺哌啶类化合物和相关化合物,这些化合物表现出作为NK-1受体拮抗剂(例如,物质P受体拮抗剂)的活性,以及含有它们的药物组合物,以及它们在治疗和预防中枢神经系统疾病、炎症性疾病、心血管疾病、眼科疾病、消化系统疾病、幽门螺杆菌引起的疾病、免疫系统疾病、尿失禁、疼痛、偏头痛、呕吐、血管生成和其他疾病的治疗中的用途。
  • [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024048A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中POL是聚合物基团,每个Hyp是独立的超支化基团,每个基团SP是独立的间隔基团,每个L是独立的可逆前药连接基团,m为0或1,每个n是独立的整数,范围从2到200,每个x是独立的0或1。此外,还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
  • USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN
    申请人:Smith-Swintosky Virginia L.
    公开号:US20070191452A1
    公开(公告)日:2007-08-16
    The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is further directed to methods for the treatment of pain comprising co-therapy with analgesic agent(s) and a compound of formula (I) as described herein.
    本发明涉及一种用于治疗疼痛的方法,包括向需要的受试者施用一种或多种新型苯并杂环磺胺衍生物的治疗有效量,其化学式如下所定义。本发明还涉及一种治疗疼痛的方法,包括与镇痛剂联合治疗以及本文描述的化合物的联合治疗。
查看更多

同类化合物

非那佐辛 酮佐辛盐酸盐 酮佐辛 莫克索兴 苄卡镇痛新 脱氧-N-苄基去甲美他佐辛 美他佐辛 环佐辛 环丙止痛胺 格各佐辛 布马佐辛 化合物 T27086 乳酸,化合物与(2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-六氢-6,11-二甲基-3-(3-甲基丁-2-烯基)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇(1:1) N-(3-氟丙基)-N-去甲美他唑新 6-乙氧基-2,2,4-三甲基-1,2-二氢喹啉 6,11-二甲基-3-丙基-1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖辛因 5-乙基-2'-羟基-2(N)-(3-甲基-2-丁烯基)-9-甲基-6,7-苯并吗吩烷 3-苄基-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 3-己基-6,11-二甲基-1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖辛因 3-(环戊基甲基)-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 3-(环丙基羰基)-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 3-(环丁基甲基)-6,11-二甲基-1,2,3,4,5,6-六氢-8-甲氧基-2,6-甲桥-3-苯并氮杂环辛四烯 2-羟基-丙酸3-(环丁基甲基)-6-乙基-1,2,3,4,5,6-六氢-11,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-基酯 2-丙烯酸,2-甲基-,聚合丁基2-丙烯酸酯,乙烯基苯,2-羟基乙基2-丙烯酸酯,甲基2-甲基-2-丙烯酸酯和噁丙环基甲基2-甲基-2-丙烯酸酯 10-(环丙基甲基)-1,13-二甲基-10-氮杂三环[7.3.1.02,7]十三-2,4,6-三烯-4-醇 1,2,3,4,5,6-六氢-6-乙基-3-甲基-(+-)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-6,11-二甲基-3-(3-甲基丁-2-烯基)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇盐酸盐 1,2,3,4,5,6-六氢-6,11-二甲基-3-(2-丙炔基)-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-环丁基甲基-6-乙基-1-甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-(环丙基甲基)-6,11-二甲基-8-甲氧基-2,6-甲桥-3-苯并氮杂环辛四烯 1,2,3,4,5,6-六氢-3-(氰基甲基)-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-(3,3-二氯-2-丙烯基)-6-乙基-11-甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 1,2,3,4,5,6-六氢-3-(3,3-二氯-2-丙烯基)-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 (2alpha,6alpha,11R*)-1,2,3,4,5,6-六氢-6,11-二甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-醇 (2S-(2a,6a,11R)-1,2,3,4,5,6-六氢-6,11-二甲基-3-(2-丙烯基)-2,6-亚甲基-3-苯并吗吩烷-8-醇盐酸盐 (-)-布马佐辛盐酸盐 (-)-去甲美他佐辛 (-)-N-丙烯基去甲变肾上腺素 盐酸盐 (-)-5,9alpha-二乙基-2'-羟基苯并吗吩烷 (+-)-(2alpha,6alpha,11R*)-苯硫代羧酸S-(1,2,3,4,5,6-六氢-3,6,11-三甲基-2,6-甲桥-3-苯并氮杂环辛四烯-8-基)酯(E)-2-丁烯二酸盐(1:1)水合物 (+)-环佐辛 (+)-喷他佐辛 (+/-)-3-(Cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-cis-6,11-dimethyl-2,6-methano-3-benzazocin-8-thiocarboxamide 8-carboxamidocyclazocine (+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-cis-6,11-dimethyl-N-(4-dimethylaminophenyl)-2,6-methano-3-benzazocin-8-amine (+)-pentazocine 5,9-dimethyl-2'-hydroxy-6,7-benzomorphan (-)-cis-2-(3,3-dimethylallyl)-5,9α-dimethyl-2'-fluoro-6,7-benzomorphan (+)-cis-2-(3,3-dimethylallyl)-5,9α-dimethyl-2'-fluoro-6,7-benzomorphan (-)-2'-fluoro-5,9α-dimethyl-6,7-benzomorphan